With an even better aim on technologies and automation expected in 2024, retaining regulatory compliance in an more and more advanced drug exploration and development continuum provides selected troubles. Automation these types of as generative AI stands to provide considerable change in the field, having said that a larger comprehending of the affect and change it will provide is imperative. Businesses will will need to evaluate the success of various technologies and strategies to regulatory processes and detect wherever synthetic intelligence can be used and where by its limitations lie.
IQVIA SMEs in the regions of Health care Facts, Safety, Regulatory and Excellent, Pharmacovigilance, Product & Tactic, offer views on what to count on in the coming yr, inroads, and options.
Synthetic Intelligence (AI)
Simon Johns, Director, Professional medical Information and Marketed Products Protection, IQVIA:
The ever-increasing quantity of Medical Information situation inquiries will carry on into